Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Celgene Corporation    CELG

Delayed Quote. Delayed  - 09/28 06:52:27 pm
106.0098 USD   -1.29%
08:01a CELGENE : Oral OTEZLA® (apremilast) Long-Term Safety Data Presented ..
09/26 CELGENE CORPORA : - A Challenging yet Rewarding Journey Towards a My..
09/21 CELGENE : Glenmark announces Strategic Development and Global Licens..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Celgene Corporation : Celgene's Profits Fall, But Focus Remains on Pipeline

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/24/2013 | 07:47pm CEST

--Celgene's Q4 net falls, while revenues rise

--FDA approval decision for multiple myeloma drug Pomalyst expected in February

--Celgene shares down 2.4% to $97.64 so far this week as investors take profits

(Updates throughout adding details and analyst comment.)

 
   By Joseph Walker and Melodie Warner 
 

Celgene Corp.'s (CELG) fourth-quarter earnings fell 36% as restructuring costs and other special items hurt the drug maker's margins and masked its increased revenue.

The results had been expected since the Summit, N.J., company pre-announced full-year results for 2012 and 2013 guidance at an investor meeting earlier this month.

Celgene's revenues jumped 13% to $1.45 billion in the quarter, largely on the strength of its core blood-cancer drug franchise, which includes the blockbuster Revlimid treatment.

However, investor attention has been focused on the company's late-stage product pipeline, which includes what Celgene says are three "potential blockbusters" that would expand the company's portfolio into new disease areas.

The first of those drugs likely to reach the market is Pomalyst, a treatment for the patients with relapsed multiple myeloma, a bone marrow cancer. The U.S. Food and Drug Administration is scheduled to make an approval decision by Feb. 10. Celgene said it would launch the drug shortly after approval.

"Our commercial and medical affairs teams are ready to launch and support the thousands of patients who have exhausted all existing myeloma therapies," Celgene Executive Vice President Mark Alles said. "Successfully launching Pomalyst is a major corporate objective and we are ready."

Celgene shares fell 0.6% to $97.64, and are down 2.4% so far this week as investors take profits. Even with the recent slide, the stock has soared 24% in 2013, as investors have placed a high premium on the company's pipeline.

Celgene also plans to seek FDA approval for apremilast, a treatment for the skin disease Psoriasis, and its cancer drug Abraxane for patients with pancreatic cancer this year. Both drugs are projected to be generate billions of dollars annually for Celgene.

The new drugs are part of Celgene's strategy to expand beyond its core hematology franchise and build out new product lines in cancer to achieve $12 billion in product sales by 2017.

Celgene reported a profit of $263.1 million, or 61 cents a share, down from $410.2 million, or 91 cents, a year earlier. Excluding items such as stock-based compensation, acquisition and restructuring costs, adjusted per-share earnings rose to $1.32 from $1.05 a year ago.

Analysts polled by Thomson Reuters had forecast earnings of $1.31 a share on revenue of $1.46 billion.

Revlimid sales jumped 17% to $1 billion, while Vidaza sales climbed 14% to $216 million.

Gross margin fell to 22.2% from 31.5% as costs rose because of preparations for the launches of Abraxane for non-small-cell lung cancer and Pomalyst. Abraxane received FDA approval for that indication in October.

Write to Joseph Walker at joseph.walker@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CELGENE CORPORATION
08:01a CELGENE : Oral OTEZLA® (apremilast) Long-Term Safety Data Presented at EADV Cong..
09/26 CELGENE CORPORATION : - A Challenging yet Rewarding Journey Towards a Myeloma Cu..
09/21 CELGENE : Glenmark announces Strategic Development and Global Licensing Agreemen..
09/21 AGIOS PHARMACEUTICALS : Appoints Andrew Hirsch as Chief Financial Officer
09/20 GLENMARK PHARMACEUTICALS : Particle to develop cancer drug
09/16 CELGENE : Oral Ozanimod Efficacy and Safety Results at 2 Years from Phase 2 RADI..
09/15 CELGENE : Announces Interim Topline Data from Trial of Investigational Oral GED-..
09/13 CELGENE : First-Ever Psoriatic Arthritis Awareness Day Aims to Educate on Import..
09/12 CELGENE CORP /DE/ : Other Events (form 8-K)
09/12 CELGENE : Announces Interim Topline Data from Trial of Investigational Oral GED-..
More news
Sector news : Bio Therapeutic Drugs
09/27DJAMGEN : Myeloma Treatment Study Fails to Meet Primary Endpoint
09/26DJPfizer Throws Out Plan to Split Into Two Companies
09/26DJSANOFI : FDA Accepts Sanofi's, Regeneron's Dermatitis Treatment for Priority Rev..
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- 2nd Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- Update
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
04:48a MY OPTIONS STRATEGY : Q3 2016
09/27 Allergan Validates Gilead Sciences NASH Pipeline
09/26 Game Plan For The Week - Cramer's Mad Money (9/23/16)
09/22 Reviewing Fortune's 20 'Best Investments' Of The Last Decade
09/22 Biotech ETF IBB Could Get A Boost From A Potential Gilead Merger Or Acquisiti..
Advertisement
Financials ($)
Sales 2016 11 080 M
EBIT 2016 5 788 M
Net income 2016 3 415 M
Debt 2016 7 253 M
Yield 2016 -
P/E ratio 2016 26,76
P/E ratio 2017 18,95
EV / Sales 2016 8,17x
EV / Sales 2017 6,72x
Capitalization 83 247 M
More Financials
Chart CELGENE CORPORATION
Duration : Period :
Celgene Corporation Technical Analysis Chart | CELG | US1510201049 | 4-Traders
Full-screen chart
Technical analysis trends CELGENE CORPORATION
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 138 $
Spread / Average Target 29%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Mark J. Alles Chief Executive Officer & Director
Jacqualyn A. Fouse President, Chief Operating Officer & Director
Robert J. Hugin Executive Chairman
Peter N. Kellogg Chief Financial Officer & Executive Vice President
Joseph S. Camardo Senior Vice President-Global Medical Affairs
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
CELGENE CORPORATION-10.32%82 402
AMGEN, INC.5.73%129 863
GILEAD SCIENCES, INC.-21.68%106 391
REGENERON PHARMACEUTIC..-22.37%42 552
VERTEX PHARMACEUTICALS..-29.17%21 876
ACTELION LTD19.91%18 591
More Results